Trial Profile
CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALK-2016
- Sponsors Pfizer
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 16 Sep 2020 Status changed from active, no longer recruiting to completed.
- 29 Jun 2020 Planned End Date changed from 18 Jun 2020 to 27 Jul 2020.